AstraZeneca’s COVID-19 vaccine has been granted emergency use authorization in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the active immunization of adults, the pharmaceutical firm said in a press statement.
According to AstraZeneca, the vaccine was shown in clinical trials to be safe and effective at preventing symptomatic COVID-19, with no severe cases and no hospitalizations more than 14 days after the second dose.
The approval in India is an important milestone as it will enable to supply India but also a large number of countries around the world, including Brazil.
AstraZeneca has partnered with Serum Institute of India (SII), the world’s largest vaccine manufacturer, for the supply of the vaccine to the Indian Government but also to a large number of low and middle-income countries.
According to the Folha de S.Paulo newspaper, Adar Poonawalla, Serum Institute‘s CEO, said on Tuesday that the AstraZeneca’s immunizer produced in India can be exported to Brazil.